PMID- 37999621
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231127
IS  - 2414-6366 (Electronic)
IS  - 2414-6366 (Linking)
VI  - 8
IP  - 11
DP  - 2023 Nov 18
TI  - Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting 
      Antivirals: Evidence from Clinical Trials and Real Life.
LID - 10.3390/tropicalmed8110502 [doi]
LID - 502
AB  - The introduction of direct-acting antiviral agents (DAAs) into clinical practice 
      has revolutionized the therapeutic approach to patients with chronic hepatitis C 
      virus (HCV) infection. According to the most recent guidelines, the first line of 
      treatment for HCV infection involves the use of one of three pan-genotypic DAA 
      combinations, sofosbuvir/velpatasvir (SOF/VEL), glecaprevir/pibrentasvir 
      (GLE/PIB), and sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX). These drugs 
      have been shown to be effective and safe in numerous clinical trials and 
      real-world studies, but special populations have been neglected. Among the 
      special populations to be treated are elderly patients, whose numbers are 
      increasing in clinical practice. The management of these patients can be 
      challenging, in particular due to multiple comorbidities, polypharmacotherapy, 
      and potential drug-drug interactions. This narrative review aims to summarize the 
      current scientific evidence on the efficacy and safety of DAAs in the elderly 
      population, both in clinical trials and in real-life settings. Although there is 
      still a paucity of real-world data and no clinical trials have yet been conducted 
      in the population aged >/= 75 years old, some considerations about the efficacy and 
      safety of DAAs in the elderly can be made based on the results of these studies. 
      The pan-genotypic associations of DAAs appear to be as efficacious and safe in 
      the elderly population as in the general population; this is both in terms of 
      similar sustained virologic response (SVR) rates and similar frequencies of 
      adverse events (AEs). However, further studies specifically involving this 
      patient population would be necessary to confirm this evidence.
FAU - Pugliese, Nicola
AU  - Pugliese N
AUID- ORCID: 0000-0001-6466-1412
AD  - Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, 
      MI, Italy.
AD  - Division of Internal Medicine and Hepatology, Department of Gastroenterology, 
      IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
FAU - Polverini, Davide
AU  - Polverini D
AD  - Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, 
      MI, Italy.
AD  - Division of Internal Medicine and Hepatology, Department of Gastroenterology, 
      IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
FAU - Arcari, Ivan
AU  - Arcari I
AD  - Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, 
      MI, Italy.
AD  - Division of Internal Medicine and Hepatology, Department of Gastroenterology, 
      IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
FAU - De Nicola, Stella
AU  - De Nicola S
AD  - Division of Internal Medicine and Hepatology, Department of Gastroenterology, 
      IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
FAU - Colapietro, Francesca
AU  - Colapietro F
AUID- ORCID: 0000-0002-7520-744X
AD  - Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, 
      MI, Italy.
AD  - Division of Internal Medicine and Hepatology, Department of Gastroenterology, 
      IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
FAU - Masetti, Chiara
AU  - Masetti C
AD  - Division of Internal Medicine and Hepatology, Department of Gastroenterology, 
      IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
FAU - Ormas, Monica
AU  - Ormas M
AD  - Division of Internal Medicine and Hepatology, Department of Gastroenterology, 
      IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
FAU - Ceriani, Roberto
AU  - Ceriani R
AUID- ORCID: 0000-0003-4838-7366
AD  - Division of Internal Medicine and Hepatology, Department of Gastroenterology, 
      IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
FAU - Lleo, Ana
AU  - Lleo A
AUID- ORCID: 0000-0002-0561-7902
AD  - Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, 
      MI, Italy.
AD  - Division of Internal Medicine and Hepatology, Department of Gastroenterology, 
      IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
FAU - Aghemo, Alessio
AU  - Aghemo A
AD  - Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, 
      MI, Italy.
AD  - Division of Internal Medicine and Hepatology, Department of Gastroenterology, 
      IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231118
PL  - Switzerland
TA  - Trop Med Infect Dis
JT  - Tropical medicine and infectious disease
JID - 101709042
PMC - PMC10674442
OTO - NOTNLM
OT  - HCV
OT  - antiviral therapy
OT  - drug-drug interactions
OT  - elderly
OT  - special populations
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/24 12:42
MHDA- 2023/11/24 12:43
PMCR- 2023/11/18
CRDT- 2023/11/24 09:55
PHST- 2023/09/19 00:00 [received]
PHST- 2023/11/09 00:00 [revised]
PHST- 2023/11/16 00:00 [accepted]
PHST- 2023/11/24 12:43 [medline]
PHST- 2023/11/24 12:42 [pubmed]
PHST- 2023/11/24 09:55 [entrez]
PHST- 2023/11/18 00:00 [pmc-release]
AID - tropicalmed8110502 [pii]
AID - tropicalmed-08-00502 [pii]
AID - 10.3390/tropicalmed8110502 [doi]
PST - epublish
SO  - Trop Med Infect Dis. 2023 Nov 18;8(11):502. doi: 10.3390/tropicalmed8110502.